Volition Veterinary Diagnostics Development LLC to Present Product Data Regarding its Nu.Q™ Vet Cancer Screening Test at the 2020 VCS Virtual Annual Conference
AUSTIN, Oct. 12, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, will present two abstracts relating to its first product, the Nu.Q™ Vet Cancer Screening Test, at the 2020 Veterinary Cancer Society (VCS) Virtual Annual Conference, which takes place from Thursday, October 15 through Saturday, October 17.
The first abstract "Characterizing Circulating Nucleosomes in the Plasma of Dogs with Lymphoma," will be presented on Friday, October 16 at 1:30 p.m. Eastern Time.
The second abstract, "Characterizing Circulating Nucleosomes in the Plasma of Dogs with Hemangiosarcoma," will be presented on Saturday, October 17 at 11:15 a.m. Eastern Time.
Volition will release further details regarding these abstracts on Friday, October 16.
Volition is proud to sponsor the 2020 VCS Virtual Annual Conference and will be providing more information about the veterinary applications of its Nucleosomics™ technology for early detection of cancer and other diseases from a virtual exhibition booth at the event.
To register for this conference click here.
The abstracts will be posted to the Volition website on Monday October 19.
Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
Nucleosomics™ and Nu.Q™ and their respective logos are trademarks of Volition and its subsidiaries.
For more information about Volition, visit Volition's website (http://www.volition.com) or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Batchelor, Volition
+44 (0)7557 774620
Scott Powell, Volition
+1 (646) 650 1351
Jen Lewis, Pegasus
+44 (0)7809 867943
Joseph Green, Edison Advisors
+1 (646) 653 7030
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the timing of the commercial launch of Volition's test platforms for early detection of cancer and other diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic or prognostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
View original content:http://www.prnewswire.com/news-releases/volition-veterinary-diagnostics-development-llc-to-present-product-data-regarding-its-nuq-vet-cancer-screening-test-at-the-2020-vcs-virtual-annual-conference-301150057.html
SOURCE VolitionRx Ltd
Released October 12, 2020